Managing acute COVID-19 in immunocompromised pediatric patients

References

• Subramaniam A, Shekar K, Afroz A, et al. Frailty and mortality associations in patients with COVID-19: a systematic review and meta-analysis. Intern Med J. 2022 May;52(5):724–739. Epub 2022 Mar 21. PMID: 35066970; PMCID: PMC9314619. doi: 10.1111/imj.15698
   PubMed Web of Science ®Google Scholar
• Kim L, Whitaker M, O’Halloran A, et al. COVID-NET Surveillance Team (2020) Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1081–1088. doi: 10.15585/mmwr.mm6932e3
   PubMed Web of Science ®Google Scholar
• Mukkada S, Bhakta N, Chantada GL, et al. Global registry of COVID-19 in childhood cancer. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021;22(10):S1470-204500454–X. doi: 10.1016/S1470-2045(21)00454-X
   Web of Science ®Google Scholar
• Bhopal SS, Bagaria J, Olabi B, et al. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5(5):e12–e13. doi: 10.1016/S2352-4642(21)00066-3
   PubMedGoogle Scholar
• Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Health. 2020;4(7):e17–e18. doi: 10.1016/S2352-4642(20)30145-0
   PubMedGoogle Scholar
• Turner D, Huang Y, Martín-de-Carpi J, et al. Paediatric IBD porto group of ESPGHAN. Corona virus disease 2019 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the paediatric IBD porto group of European society of paediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2020 Jun;70:727–733. PMID: 32443020; PMCID: PMC7273950. doi: 10.1097/MPG.0000000000002729
   PubMed Web of Science ®Google Scholar
• Sengler C, Eulert S, Minden K, et al. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National paediatric rheumatology database in Germany. RMD Open. 2021 Jul;7:e001687. PMID: 34312307; PMCID: PMC8316693. doi: 10.1136/rmdopen-2021-001687
   PubMed Web of Science ®Google Scholar
• Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch Med Res. 2022;53(1):1–8. ISSN 0188-4409. doi: 10.1016/j.arcmed.2021.07.002
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Amin-Chowdhury Z, Davies HG, et al. COVID-19 in children: analysis of the first pandemic peak in England. Arch Dis Child. 2020;105:1180–1185. doi: 10.1136/archdischild-2020-320042
   PubMed Web of Science ®Google Scholar
• Parri N, Lenge M, Buonsenso D. Children with COVID-19 in pediatric emergency departments in Italy. New Engl J Med. 2020;383(2):187–190. doi: 10.1056/NEJMc2007617
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• [cited 2023 Mar 20]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-schools
   Google Scholar
• Ledford H. Deaths from COVID ‘incredibly rare’ among children. Nature. 2021;595(7869):639. doi: 10.1038/d41586-021-01897-w
   Web of Science ®Google Scholar
• Greenan-Barrett J, Ciurtin C. COVID-19 in immunocompromised children and adolescents. Pediatr Infect Dis J. 2022 Oct;41:e424–e427. doi: 10.1097/INF.0000000000003605
   PubMed Web of Science ®Google Scholar
• Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. 2022 Feb 7;37:e35. PMID: 35132841; PMCID: PMC8822112. doi: 10.3346/jkms.2022.37.e35
   PubMed Web of Science ®Google Scholar
• Martin B, DeWitt PE, Russell S, et al. Characteristics, outcomes, and severity risk factors associated with SARS-CoV-2 infection among children in the US National COVID cohort Collaborative. JAMA Netw Open. 2022;5:e2143151. doi: 10.1001/jamanetworkopen.2021.43151
   PubMed Web of Science ®Google Scholar
• Chappell H, Patel R, Driessens C, et al. Immunocompromised children and young people are at no increased risk of severe COVID-19. J Infect. 2022;84(1):31–39. ISSN 0163-4453. doi: 10.1016/j.jinf.2021.11.005
   PubMed Web of Science ®Google Scholar
• Belsky JA, Tullius BP, Lamb MG, et al. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021 Mar;82(3):329–338. Epub 2021 Feb 4. PMID: 33549624; PMCID: PMC7859698. doi: 10.1016/j.jinf.2021.01.022
   PubMed Web of Science ®Google Scholar
• Kuczborska K, Buda P, Książyk J. Long-COVID in immunocompromised children. Eur J Pediatr. 2022;181:3501–3509. doi: 10.1007/s00431-022-04561-1
   PubMed Web of Science ®Google Scholar
• Teoh Z, Danziger-Isakov L, Courter JD, et al. Tocilizumab for treatment of children and young adults with severe acute COVID-19: experience at a quaternary-care children’s hospital. Pediatr Infect Dis J. 2023 Feb 1;42(2): 119–121. Epub 2022 Oct 29. PMID: 36638396; PMCID: PMC9838604. doi: 10.1097/INF.0000000000003763
   PubMed Web of Science ®Google Scholar
• [cited 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-approval-comirnaty-spikevax-covid-19-vaccines-children-6-months-age
   Google Scholar
• Mercolini F, Cesaro S. COVID-19 in children and adolescents: characteristics and specificities in immunocompetent and oncohematological patients. Mediterr J Hematol Infect Dis. 2022 Jan 1. 14(1):e2022009. PMID: 35070216; PMCID: PMC8747159. doi: 10.4084/MJHID.2022.009
   PubMedGoogle Scholar
• Delmonte OM, Castagnoli R, Notarangelo LD et al. COVID-19 and inborn errors of immunity. Physiology. 2022 Nov 1;37(6): 290–301. Epub 2022 Aug 9. PMID: 35944006; PMCID: PMC9550578. doi: 10.1152/physiol.00016.2022
   Web of Science ®Google Scholar
• Connelly JA, Chong H, Esbenshade AJ, et al. Impact of COVID-19 on Pediatric Immunocompromised Patients. Pediatr Clin North Am. 2021 Oct;68(5):1029–1054. Epub 2021 May 26. PMID: 34538297; PMCID: PMC8149202. doi: 10.1016/j.pcl.2021.05.007
   PubMed Web of Science ®Google Scholar
• Arrigo S, Alvisi P, Banzato C, et al. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: a position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021 Feb;53(2):183–189. Epub 2020 Oct 22. PMID: 33132063; PMCID: PMC7580561. doi: 10.1016/j.dld.2020.10.024
   PubMedGoogle Scholar
• Dipasquale V, Deganello Saccomani M, Di Giorgio A, et al. Pediatric gastroenterology and hepatology in Italy before and after the COVID-19: lessons learned and management changes by SIGENP. Ital J Pediatr. 2023 Jan 26;49:15. PMID: 36698148; PMCID: PMC9877500. doi: 10.1186/s13052-023-01418-7
   PubMed Web of Science ®Google Scholar
• Morello W, Vianello FA, Proverbio E, et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol. 2022 Apr;37:757–764. Epub 2021 Oct 23. PMID: 34687377; PMCID: PMC8536471. doi: 10.1007/s00467-021-05330-2
   PubMed Web of Science ®Google Scholar
• Feldman AG, Danziger-Isakov LA. The impact of COVID-19 on the pediatric solid organ transplant population. Semin Pediatr Surg. 2022 Jun;31(3):151178. Epub 2022 May 14. PMID: 35725046; PMCID: PMC9107330. doi: 10.1016/j.sempedsurg.2022.151178
   PubMed Web of Science ®Google Scholar
• Nicastro E, Ebel NH, Kehar M, et al. The impact of severe acute respiratory syndrome coronavirus type 2 on children with liver diseases: a Joint European society for pediatric gastroenterology, hepatology and nutrition and society of pediatric liver transplantation position paper. J Pediatr Gastroenterol Nutr. 2022 Jan 1;74(1): 159–170. PMID: 34694269; PMCID: PMC8673661. doi: 10.1097/MPG.0000000000003339
   PubMed Web of Science ®Google Scholar
• [cited 2023 Mar 27]. Available from: https://ginasthma.org/wp-content/uploads/2022/05/COVID-19-and-asthma-GINA-22_04_30.pdf
   Google Scholar
• [cited 2023 Mar 27]. Available from: https://escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
   Google Scholar
• Bisogno G, Provenzi M, Zama D, et al. Clinical Characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in Italian pediatric Oncology patients: a study from the infectious diseases working group of the associazione Italiana di oncologia e Ematologia Pediatrica. J Pediatric Infect Dis Soc. 2020 Nov;9(5):530–534.
   PubMed Web of Science ®Google Scholar
• Katato GK, Sitaula P, Gupte A, et al. The impact of COVID-19 on pediatric malignancy diagnosis and treatment: never the same but lessons learned. Vaccines (Basel). 2023 Mar 15;11:667. PMID: 36992251; PMCID: PMC10052576. doi: 10.3390/vaccines11030667
   PubMed Web of Science ®Google Scholar
• Zama D, Baccelli F, Colombini A, et al. Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the infectious diseases working group of the associazione Italiana di ematologia e Oncologia Pediatrica (AIEOP). Ann Hematol. 2022 Aug;101:1843–1851. Epub 2022 Jun 20. PMID: 35726104; PMCID: PMC9208706. doi: 10.1007/s00277-022-04884-x
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/Severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2021 Feb 13;10:34–48. PMID: 32918548; PMCID: PMC7543452. doi: 10.1093/jpids/piaa115
   PubMed Web of Science ®Google Scholar
• [cited 2023 -Aug 10]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/
   Google Scholar
• Del Borrello G, Giraudo I, Bondone C, et al. SARS-COV-2–associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost. 2021 Feb;19(2):522–530. Epub 2020 Dec 23. PMID: 33305475; PMCID: PMC9906296. doi: 10.1111/jth.15216
   PubMed Web of Science ®Google Scholar
• Whitworth H, Sartain SE, Kumar R, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021 Jul 15;138:190–198. PMID: 33895804; PMCID: PMC8079262. doi: 10.1182/blood.2020010218
   PubMed Web of Science ®Google Scholar
• Goldenberg NA, Sochet A, Albisetti M, et al. Pediatric/Neonatal hemostasis and thrombosis subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020 Nov;18:3099–3105. PMID: 33174388; PMCID: PMC9906345. doi: 10.1111/jth.15073
   PubMed Web of Science ®Google Scholar
• Loi M, Branchford B, Kim J, et al. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer. 2020 Sep;67(9):e28485. Epub 2020 Jun 18. PMID: 32558124; PMCID: PMC7323104. doi: 10.1002/pbc.28485
   PubMed Web of Science ®Google Scholar
• La Tessa A, Motisi MA, Marseglia GL, et al. Use of remdesivir in children with COVID-19 infection: a quick narrative review. Acta Biomed. 2021 Nov 29;92(S7): e2021524. PMID: 34842595; PMCID: PMC9431884. doi: 10.23750/abm.v92iS7.12396
   PubMedGoogle Scholar
• Wang Z, Zhao S, Tang Y, et al. Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. Eur J Pediatr. 2022 May;181:2135–2146. Epub 2022 Feb 22. PMID: 35192051; PMCID: PMC8861482. doi: 10.1007/s00431-022-04388-w
   PubMed Web of Science ®Google Scholar
• [cited 2023 Aug 10]. Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0338/2021-ema-decision-9-august-2021-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
   Google Scholar
• Méndez-Echevarría A, Pérez-Martínez A, Gonzalez Del Valle L, et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr. 2021 Apr;180:1317–1322. Epub 2020 Nov 16. PMID: 33200304; PMCID: PMC7668659. doi: 10.1007/s00431-020-03876-1
   PubMed Web of Science ®Google Scholar
• Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics. 2021 May;147:e2020047803. PMID: 33883243. doi: 10.1542/peds.2020-047803
   PubMed Web of Science ®Google Scholar
• Esposito S, Autore G, Argentiero A, et al. Update on COVID-19 therapy in pediatric age. Pharmaceuticals (Basel). 2022 Dec 5;15:1512. PMID: 36558963; PMCID: PMC9783267. doi: 10.3390/ph15121512
   PubMedGoogle Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. EPIC-HR investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022 Apr 14;386:1397–1408. Epub 2022 Feb 16. PMID: 35172054; PMCID: PMC8908851. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 Feb 10;S1473-3099(23):00011–7. Epub ahead of print. PMID: 36780912; PMCID: PMC10014040. doi: 10.1016/S1473-3099(23)00011-7
   Google Scholar
• Wolf J, Abzug MJ, Anosike BI, et al. Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc. 2022 May 30;11(5): 177–185. PMID: 35107571; PMCID: PMC8903349. doi: 10.1093/jpids/piab124
   PubMed Web of Science ®Google Scholar
• Cesaro S, Mikulska M, Hirsch HH, et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European conference on infections in leukaemia (ECIL 9). Leukemia. 2023 Jul 17;37(9):1933–1938. Epub ahead of print. PMID: 37460673. doi: 10.1038/s41375-023-01938-5
   PubMed Web of Science ®Google Scholar
• Romani L, Calò Carducci FI, Chiurchiù S, et al. Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection. Children (Basel). 2022 Mar 7;9:369. PMID: 35327741; PMCID: PMC8947030. doi: 10.3390/children9030369
   PubMed Web of Science ®Google Scholar
• Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2022 Aug 24;75(1): e440–e449. PMID: 34718468; PMCID: PMC9402688. doi: 10.1093/cid/ciab912
   PubMed Web of Science ®Google Scholar
• Pruccoli G, Bertorello N, Funiciello E, et al. A single-center experience in treating young children at high risk for severe COVID-19 with sotrovimab. Pediatr Infect Dis J. 2022 Aug 1;41(8): e341–e342. Epub 2022 Jul 13. PMID: 35421051; PMCID: PMC9281427. doi: 10.1097/INF.0000000000003552
   PubMed Web of Science ®Google Scholar
• Ling KM, Dougan M. Monoclonal antibodies for the treatment of COVID-19 infection in children. Expert Rev Anti Infect Ther. 2022 Dec;20(12):1529–1535. Epub 2022 Oct 19. PMID: 36225144. doi: 10.1080/14787210.2022.2134117
   PubMed Web of Science ®Google Scholar
• [cited 2023 Mar 28]. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern.
   Google Scholar
• Das NC, Chakraborty P, Bayry J, et al. In silico analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant Spike protein. Front Immunol. 2022 Jan 10;12:782506. PMID: 35082779; PMCID: PMC8784557. doi: 10.3389/fimmu.2021.782506
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021 Feb 25;384; 693–704. Epub 2020 Jul 17. PMID: 32678530; PMCID: PMC7383595. doi: 10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• Chauvin C, Levillayer L, Roumier M, et al. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience. 2023 Mar 17;26(3): 106124. Epub 2023 Feb 3. PMID: 36776936; PMCID: PMC9894676. doi: 10.1016/j.isci.2023.106124
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022 Jul 30;400(10349):359–368. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. PMID: 35908569; PMCID: PMC9333998. doi: 10.1016/S0140-6736(22)01109-6
   PubMed Web of Science ®Google Scholar
• Thompson MA, Henderson JP, Shah PK, et al. COVID-19 and cancer consortium. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021 Jun 17;7(8):1167–1175. Epub ahead of print. Erratum in: JAMA Oncol. 2021 Aug 1;7:1249. PMID: 34137799; PMCID: PMC8377563. doi:10.1001/jamaoncol.2021.1799
   PubMed Web of Science ®Google Scholar
• Zaffanello M, Piacentini G, Nosetti L, et al. The use of convalescent plasma for pediatric patients with SARS-CoV-2: a systematic literature review. Transfus Apher Sci. 2021 Apr;60(2):103043. Epub 2020 Dec 23. PMID: 33388249; PMCID: PMC7834628. doi: 10.1016/j.transci.2020.103043
   PubMed Web of Science ®Google Scholar
• Sullivan DJ, Franchini M, Senefeld JW, et al. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1. J Gen Virol. 2023 May;104(5):001854. PMID: 37167085; PMCID: PMC10336427. doi: 10.1099/jgv.0.001854
   PubMed Web of Science ®Google Scholar
• Sullivan DJ, Franchini M, Joyner MJ, et al. Analysis of anti-SARS-CoV-2 omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun. 2022 Oct 29;13:6478. PMID: 36309490; PMCID: PMC9617541. doi: 10.1038/s41467-022-33864-y
   PubMed Web of Science ®Google Scholar
• Denkinger CM, Janssen M, Schäkel U, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023 Jan;4(1):96–107. Epub 2022 Dec 29. PMID: 36581734; PMCID: PMC9886549. doi: 10.1038/s43018-022-00503-w
   PubMedGoogle Scholar
• Mitchell R, Cayen J, Thampi N, et al. Trends in severe outcomes among adult and pediatric patients hospitalized with COVID-19 in the Canadian nosocomial infection surveillance program, March 2020 to May 2022. JAMA Netw Open. 2023 Apr 3;6(4): e239050. PMID: 37079304; PMCID: PMC10119741. doi: 10.1001/jamanetworkopen.2023.9050
   PubMed Web of Science ®Google Scholar
• Marra AR, Kobayashi T, Suzuki H, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. J Infect. 2022 Mar;84(3):297–310. Epub 2022 Jan 1. PMID: 34982962; PMCID: PMC8720049. doi: 10.1016/j.jinf.2021.12.035
   PubMed Web of Science ®Google Scholar
• Javadinia SA, Alizadeh K, Mojadadi MS, et al. COVID-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol. 2022 May 2;13:860238. PMID: 35586627; PMCID: PMC9108702. doi: 10.3389/fendo.2022.860238
   PubMed Web of Science ®Google Scholar
• Mehrabi Nejad MM, Shobeiri P, Dehghanbanadaki H, et al. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis. Virol J. 2022 Aug 8;19:132. PMID: 35941646; PMCID: PMC9358061. doi: 10.1186/s12985-022-01858-3
   PubMed Web of Science ®Google Scholar
• Cesaro S, Muggeo P, Zama D, et al. Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian association of pediatric Hematology Oncology. J Clin Med. 2022 Feb 24;11(5): 1235. PMID: 35268326; PMCID: PMC8911119. doi: 10.3390/jcm11051235
   PubMed Web of Science ®Google Scholar
• Kubas A, Malecka-Wojciesko E. COVID-19 vaccination in inflammatory bowel disease (IBD). J Clin Med. 2022 May 9. 1(9):2676. PMID: 35566802; PMCID: PMC9104993. doi: 10.3390/jcm11092676
   Google Scholar
• Murdaca G, Noberasco G, Olobardi D, et al. Current take on systemic sclerosis patients’ vaccination recommendations. Vaccines (Basel). 2021 Dec 2;9:1426. PMID: 34960174; PMCID: PMC8708328. doi: 10.3390/vaccines9121426
   PubMed Web of Science ®Google Scholar
• Lawson-Tovey S, Machado PM, Strangfeld A, et al. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. RMD Open. 2022 Jul;8:e002322. PMID: 35908834; PMCID: PMC9344592. doi: 10.1136/rmdopen-2022-002322
   PubMed Web of Science ®Google Scholar
• Kastl AJ, Weaver KN, Zhang X, et al. Humoral immune response and safety of SARS-CoV-2 vaccination in pediatric inflammatory bowel disease. Am J Gastroenterol. 2023 Jan 1;118:129–137. Epub 2022 Sep 16. PMID: 36114773. doi: 10.14309/ajg.0000000000002016
   PubMed Web of Science ®Google Scholar
• Pulvirenti F, Fernandez Salinas A, Milito C, et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. Cells. 2021 Oct 27;10:2915. PMID: 34831138; PMCID: PMC8616496. doi: 10.3390/cells10112915
   PubMed Web of Science ®Google Scholar